An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption

Dulaglutide is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist that has shown a durable glycemic efficacy as well as beneficial effects on body weight and major adverse cardiovascular events (MACE) outcomes, making it an important option for the treatment of type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriakos, Georgios, Diamantis, Evangelos, Memi, Eleni, Elefsiniotis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864188/
https://www.ncbi.nlm.nih.gov/pubmed/35223310
http://dx.doi.org/10.7759/cureus.21536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864188/
https://www.ncbi.nlm.nih.gov/pubmed/35223310
http://dx.doi.org/10.7759/cureus.21536

Ejemplares similares